Skip to content
SSR-Health-CMYK-176x126
  • Home
  • About Us
    • Team
    • In the Media
    • In the Literature
  • Contact
  • Home
  • About Us
    • Team
    • In the Media
    • In the Literature
  • Contact
SSR-Health-CMYK-176x126
  • Home
  • About Us
    • Team
    • In the Media
    • In the Literature
  • Contact
  • Home
  • About Us
    • Team
    • In the Media
    • In the Literature
  • Contact

LLY: Whether High R&D/Sales is Defensible – an Empiric Dissent

  • Post author:Richard Evans
  • Post published:October 24, 2013
  • Post category:Current/Hidden Pipeline/Major pharmaceuticals/R&D Productivity

On October 20, the Wall Street Journal published an interview with LLY’s CEO, addressing the question of whether LLY’s relatively high R&D spending versus peers (Exhibit 1) is warranted. With…

Continue ReadingLLY: Whether High R&D/Sales is Defensible – an Empiric Dissent

Contact Us

Twitter Linkedin

© Copyright 2025. SSR Health, LLC

Contact Us

Linkedin

© Copyright 2025. SSR Health, LLC